Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab added to (R)-GemOx for relapsed or progressive aggressive non-Hodgkin lymphoma in transplant-ineligible older or comorbid adults
MOH_2020-03-03_008744Phase 3Not yet recruiting
- Sponsor
- Saarland University
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab in non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma and 4 more (2 arms), sponsored by Saarland University. Primary endpoint: 1-year progression-free survival. Planned start Feb 2020; status: not yet recruiting.
02
Drugs
03
Conditions
non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)large-cell lymphomaprimary mediastinal large B-cell lymphoma (PMBCL)peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on MOH_2020-03-03_008744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-03-03_008744.